CN103396328A - Meclofenoxate hydrochloride compound and pharmaceutical composition thereof - Google Patents

Meclofenoxate hydrochloride compound and pharmaceutical composition thereof Download PDF

Info

Publication number
CN103396328A
CN103396328A CN2013103658460A CN201310365846A CN103396328A CN 103396328 A CN103396328 A CN 103396328A CN 2013103658460 A CN2013103658460 A CN 2013103658460A CN 201310365846 A CN201310365846 A CN 201310365846A CN 103396328 A CN103396328 A CN 103396328A
Authority
CN
China
Prior art keywords
meclofenoxate hydrochloride
hydrochloride compound
preparation
meclofenoxate
drug combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2013103658460A
Other languages
Chinese (zh)
Other versions
CN103396328B (en
Inventor
李美林
马虹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUNAN WUZHOUTONG PHARMACEUTICAL CO., LTD.
Original Assignee
HUBEI MERRYCLIN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUBEI MERRYCLIN PHARMACEUTICAL CO Ltd filed Critical HUBEI MERRYCLIN PHARMACEUTICAL CO Ltd
Priority to CN201310365846.0A priority Critical patent/CN103396328B/en
Publication of CN103396328A publication Critical patent/CN103396328A/en
Application granted granted Critical
Publication of CN103396328B publication Critical patent/CN103396328B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

A meclofenoxate hydrochloride compound is a crystal. Determined by X-ray powder diffraction, the meclofenoxate hydrochloride compound has characteristic peaks at 2theta +/- 0.2 degree of 6.1 degrees, 7.7 degrees, 9.3 degrees, 12.2 degrees, 14.3 degrees, 17.8 degrees, 18.9 degrees, 20.5 degrees, 22.2 degrees, 23.3 degrees, 24.5 degrees, 25.8 degrees and 27.0 degrees in the spectrum pattern. The invention also discloses a pharmaceutical composition of the meclofenoxate hydrochloride compound. The dosage forms of the pharmaceutical composition comprise dispersing tablets, capsules, freeze-dried powder injection, and aseptic powder for injection. The meclofenoxate hydrochloride compound has extremely good fluidity as well as stable quality. The benefits comprise that the dispersing tablets, the capsules and the freeze-dried powder injection of the prepared meclofenoxate hydrochloride compound has good stability and low impurity content.

Description

Meclofenoxate hydrochloride compound and pharmaceutical composition thereof
Technical field
The invention belongs to medical technical field, meclofenoxate hydrochloride compound and pharmaceutical composition thereof.
Background technology
Meclofenoxate hydrochloride, chemical name: 2-(dimethylamino) ethyl parachlorophen-oxyacetic acid ester hydrochloride.The meclofenoxate hydrochloride Main Function is in pallium, and it can promote the redox of brain cell, regulates the metabolism of neurocyte, and the utilization that increases carbohydrate has excitation to downtrod nervus centralis.Be applicable to traumatic stupor, children enuresis, the disturbance of consciousness, senile psychosis, various dementia, alcoholism etc.
The meclofenoxate hydrochloride less stable, and in molecule because containing ester bond, the aqueous solution is unstable, facile hydrolysis.Aqueous solution pH raises, and hydrolysis rate is accelerated.In order to address this problem, prior art generally attempts from the preparation aspect addressing this problem, and the means of use are add auxiliary material and adopt than complicated technology, and overcome its unstable.Although improving the stability of meclofenoxate hydrochloride aspect preparation, prior art have certain effect still to need to add more auxiliary material and need to coordinate the comparatively technique of complexity, although there have certain effect still to act on to be limited, limited the application of meclofenoxate hydrochloride,, because the facile hydrolysis meclofenoxate hydrochloride is unstable in feed stage, need high preservation condition.the prior art that also has attempts obtaining from changing crystal formation the meclofenoxate hydrochloride of higher stability, as: China application CN103214382A, the meclofenoxate hydrochloride compound that this application provides and drug regimen thereof are compared with prior art, have better stability in storage and mobility, the inventor finds in test, although the meclofenoxate hydrochloride that obtains in this application has stability preferably under normal temperature and acceleration environment, but less stable in the factorial experiments of other influences drug quality, especially still have higher draw moist, make the easy water of hydroscopicity solution of meclofenoxate hydrochloride.Obtained unexpectedly a kind of meclofenoxate hydrochloride compound of crystalline form in order to address this problem the inventor in long-term a large amount of research process, this compound draws moist very low, is difficult for the water of hydroscopicity solution and has high quality stability.It is composite preparation of meclofenoxate hydrochloride compound of the present invention and preparation method thereof that the present invention also provides effective constituent, the preparation that can be prepared into according to content of the present invention, keep high stability, obviously be better than commercially available kind, greatly improved security, validity that meclofenoxate hydrochloride uses.
Summary of the invention
The invention provides a kind of stable meclofenoxate hydrochloride compound and drug combination preparation thereof.
Meclofenoxate hydrochloride structural formula of compound provided by the invention is as shown in formula I:
Formula I
Described meclofenoxate hydrochloride compound is crystal, adopt the X-ray powder diffraction to measure, in its collection of illustrative plates, characteristic peak ° is 6.1 °, 7.7 °, 9.3 °, 12.2 °, 14.3 °, 17.8 °, 18.9 °, 20.5 °, 22.2 °, 23.3 °, 24.5 °, 25.8 °, 27.0 ° demonstrations in 2 θ ± 0.2.
The X-ray powder diffraction figure of described meclofenoxate hydrochloride compound sees Fig. 1.
The fusing point of described meclofenoxate hydrochloride compound is 147~152 ℃.
Meclofenoxate hydrochloride compounds process for production thereof of the present invention comprises the steps:
1) the meclofenoxate hydrochloride raw material being added volume ratio by weight 1:15~1:18 is that in the mixing solutions of the trichloromethane of 9:1 and ethanol, the regulator solution temperature is 30~35 ℃, stirring and dissolving.
2) keeping solution temperature is 30~35 ℃, and adding weight is the gac of meclofenoxate hydrochloride weight 0.7%, and 120~150 rev/mins were stirred 25 minutes, filtered carbon removal, and filtrate, through 0.22 μ m membrane filtration, is obtained filtrate.
3) regulating the filtrate temperature is 22~27 ℃, under the stirring velocity of 90~110 rev/mins, slowly at the uniform velocity drip weight in the filtrate that obtains take 50ml~75ml/min speed toward step 2 while stirring and be the ether of 8:2 and the mixing solutions of sherwood oil as the volume ratio of 10~12 times of trichloromethane in step 1 and alcohol mixtures; Simultaneously with 0.5~0.7 ℃/min speed, be cooled to 8~10 ℃, stop stirring, with 0.2~0.4 ℃/min speed, be cooled to 2~4 ℃ of standing growing the grains 6 hours, filter.
4) wash 2 times with the ether of 2 times of weight filtering the filter cake obtain in step 3,47 ℃~52 ℃ dryings 8 hours, namely obtain described meclofenoxate hydrochloride compound.
Meclofenoxate hydrochloride raw material in meclofenoxate hydrochloride compound preparation process of the present invention is the marketable material medicine.
It is the drug combination preparation of meclofenoxate hydrochloride compound of the present invention that the present invention's the second purpose is to provide effective constituent, and described drug combination preparation is dispersible tablet, capsule, freeze-dried powder and injectable sterile powder.Characteristics based on the meclofenoxate hydrochloride of the present invention preparation, can the meclofenoxate hydrochloride of the present invention's preparation be made several formulations with existing public technology, but in order to obtain the more better meclofenoxate hydrochloride preparation of high quality of stability, the preferred following technical scheme of the present invention:
Described freeze-dried powder contains pharmacy acceptable vehicle carrier, and vehicle can be one or more of N.F,USP MANNITOL, glucose, dextran, lactose, preferred N.F,USP MANNITOL, and the preparation solvent is water for injection.
Preferred every of described lyophilized injectable powder contains meclofenoxate hydrochloride compound 0.06g of the present invention, N.F,USP MANNITOL 0.24g or meclofenoxate hydrochloride compound 0.25g, N.F,USP MANNITOL 0.05g or meclofenoxate hydrochloride compound 0.1g, N.F,USP MANNITOL 0.1g and meclofenoxate hydrochloride compound 0.2g, N.F,USP MANNITOL 0.2g.
The preparation method of described lyophilized injectable powder comprises the steps:
1, add to by meclofenoxate hydrochloride compound 60g, N.F,USP MANNITOL 240g, water for injection that 2000ml or meclofenoxate hydrochloride compound 250g, N.F,USP MANNITOL 50g, water for injection add to 2000ml or meclofenoxate hydrochloride compound 100g, N.F,USP MANNITOL 100g, water for injection adds to 2000ml.The meclofenoxate hydrochloride compound of recipe quantity is added in the water for injection of 1400ml, and stirring and dissolving, inject water to 1600ml, then by recipe quantity, adds the N.F,USP MANNITOL stirring and dissolving, injects water to 2000ml, stirs.
2, add 0.10%(g/ml in 1) gac, stirred 20 minutes, filtering decarbonization, 0.22 μ m membrane filtration degerming, carry out intermediate and detect.
3, freeze-drying:
1. pre-freeze: filtrate packing false add in 2 is plugged in being cooled in advance-24 ℃~-22 ℃ refrigerated tanks, kept 1.5 hours, with 0.6 ℃/min~0.8 ℃/min speed, be cooled to-38 ℃~-33 ℃, be incubated 2 hours;
2. distillation: open vacuum unit, control vacuum tightness is 14~17Pa, with 0.5 ℃/min~0.7 ℃/min speed, at the uniform velocity is warming up to-14 ℃~-12 ℃, in this temperature, keeps 1 hour, at the uniform velocity be warming up to-2 ℃~3 ℃ with 0.3 ℃/min~0.5 ℃/min speed, in this temperature, kept 5 hours.
3. dry: at the uniform velocity be warming up to 40 ℃~43 ℃ with 0.7 ℃/min~0.9 ℃/min speed, dry 6 hours, packing namely obtained described meclofenoxate hydrochloride freeze-dried powder after the assay was approved.
The inventor finds that the meclofenoxate hydrochloride compound that the present invention prepares also has the fabulous characteristic of mobility except steady quality under study for action, for this characteristic, through large quantity research, screening high amount of drug auxiliary material carrier combinations comprises one or more of starch, pregelatinized Starch, talcum powder, N.F,USP MANNITOL, Microcrystalline Cellulose, lactose, Xylo-Mucine, hydroxypropylcellulose, Magnesium Stearate, sodium starch glycolate, preferred pregelatinized Starch.
When described drug combination preparation capsule, preferred specification is meclofenoxate hydrochloride 0.2g and meclofenoxate hydrochloride 0.1g.
The prescription of described meclofenoxate hydrochloride composition capsule is:
Meclofenoxate hydrochloride compound: 200g
Pregelatinized Starch: 50g
Its preparation method is:
1, will cross successively 80 mesh sieves through meclofenoxate hydrochloride compound, the pregelatinized Starch of 60 ℃ of dryings in advance.
2, each supplementary material is fully mixed rear mensuration content, according to specification, determine loading amount, with the capsule packing machine, be packed into capsule, check, packing, obtain the medicament composition capsule that effective constituent is meclofenoxate hydrochloride of the present invention.
When described drug combination preparation dispersible tablet, preferred specification is meclofenoxate hydrochloride 0.1g.
The prescription of described meclofenoxate hydrochloride composition dispersible tablet is:
Meclofenoxate hydrochloride compound: 200g
Microcrystalline Cellulose: 50g
Its preparation method is:
1, will cross successively 80 mesh sieves through meclofenoxate hydrochloride compound, the Microcrystalline Cellulose of 60 ℃ of dryings in advance.
2, each supplementary material is fully mixed rear mensuration content, according to specification, determine the sheet weight, upper machine compressing tablet, check, packing, obtain the medicament combination dispersible tablet that effective constituent is meclofenoxate hydrochloride of the present invention.
When described drug combination preparation injectable sterile powder, preferred specification is meclofenoxate hydrochloride 0.1g or 0.06g or 0.25g or 0.2g.
Its preparation method is:
Under hundred grades of aseptic conditions, the meclofenoxate hydrochloride compound is undertaken aseptic subpackaged by specification, obtain the injectable sterile powder that effective constituent is meclofenoxate hydrochloride of the present invention.
Description of drawings
Fig. 1 is the X-ray powder diffraction pattern of the meclofenoxate hydrochloride compound of the embodiment of the present invention 1 preparation.
Embodiment
The preparation of embodiment 1 meclofenoxate hydrochloride compound
1. the meclofenoxate hydrochloride raw material being added volume ratio by weight 1:15 is that in the mixing solutions of the trichloromethane of 9:1 and ethanol, the regulator solution temperature is 30 ℃, stirring and dissolving.
2. keeping solution temperature is 30 ℃, and adding weight is the gac of meclofenoxate hydrochloride weight 0.7%, and 120 rev/mins were stirred 25 minutes, filtered carbon removal, and filtrate, through 0.22 μ m membrane filtration, is obtained filtrate;
3. regulating the filtrate temperature is 22 ℃, under the stirring velocity of 90 rev/mins, slowly at the uniform velocity drip weight in the filtrate that obtains take 50ml/min speed toward step 1 while stirring and be the ether of 8:2 and the mixing solutions of sherwood oil as the volume ratio of 10 times of trichloromethane in step 1 and alcohol mixtures; Simultaneously with 0.5 ℃/min speed, be cooled to 8 ℃, stop stirring, with 0.2 ℃/min speed, be cooled to 2 ℃ of standing growing the grains 6 hours, filter.
4. wash 2 times with the ether of 2 times of weight filtering the filter cake obtain in step 3,47 ℃ of dryings 8 hours, namely obtain described meclofenoxate hydrochloride compound.
The X-ray powder diffraction pattern is seen accompanying drawing 1, and in its collection of illustrative plates, characteristic peak ° is 6.1 °, 7.7 °, 9.3 °, 12.2 °, 14.3 °, 17.8 °, 18.9 °, 20.5 °, 22.2 °, 23.3 °, 24.5 °, 25.8 °, 27.0 ° demonstrations in 2 θ ± 0.2.Content: 99.90%.Fusing point: 147~152 ℃.
The preparation of embodiment 2 meclofenoxate hydrochloride compounds
1. the meclofenoxate hydrochloride raw material being added volume ratio by weight 1:18 is that in the mixing solutions of the trichloromethane of 9:1 and ethanol, the regulator solution temperature is 35 ℃, stirring and dissolving.
2. keeping solution temperature is 35 ℃, and adding weight is the gac of meclofenoxate hydrochloride weight 0.7%, and 150 rev/mins were stirred 25 minutes, filtered carbon removal, and filtrate, through 0.22 μ m membrane filtration, is obtained filtrate;
3. regulating the filtrate temperature is 27 ℃, under the stirring velocity of 110 rev/mins, slowly at the uniform velocity drip weight in the filtrate that obtains take 75ml/min speed toward step 2 while stirring and be the ether of 8:2 and the mixing solutions of sherwood oil as the volume ratio of 12 times of trichloromethane in step 1 and alcohol mixtures; Simultaneously with 0.7 ℃/min speed, be cooled to 10 ℃, stop stirring, with 0.4 ℃/min speed, be cooled to 4 ℃ of standing growing the grains 6 hours, filter.
4. wash 2 times with the ether of 2 times of weight filtering the filter cake obtain in step 3,52 ℃ of dryings 8 hours, namely obtain described meclofenoxate hydrochloride compound.
The X-ray powder diffraction pattern is consistent with embodiment.Content: 99.91%.Fusing point: 147~152 ℃.
Preparation (the specification: 0.06g) of embodiment 3 meclofenoxate hydrochloride freeze-dried powders
Prescription:
Meclofenoxate hydrochloride compound: 60g
N.F,USP MANNITOL: 240g
Water for injection adds to 2000ml
Make 1000
Technique:
1, the meclofenoxate hydrochloride of recipe quantity is added in the water for injection of 1400ml, stirring and dissolving, inject water to 1600ml, then by recipe quantity, adds the N.F,USP MANNITOL stirring and dissolving, injects water to 2000ml, stirs.
2, add 0.10%(g/ml in 1) gac, stirred 20 minutes, filtering decarbonization, 0.22 μ m membrane filtration degerming, carry out intermediate and detect.
3, freeze-drying:
1. pre-freeze: filtrate packing false add in 2 is plugged in being cooled in advance-24 ℃ of refrigerated tanks, kept 1.5 hours, with 0.6 ℃/min speed, be cooled to-38 ℃, be incubated 2 hours;
2. distillation: open vacuum unit, control vacuum tightness is 14Pa, with 0.5 ℃/min speed, at the uniform velocity is warming up to-14 ℃, in this temperature, keeps 1 hour, with 0.3 ℃/min speed, at the uniform velocity is warming up to-2 ℃, in this temperature, keeps 5 hours.
3. dry: at the uniform velocity be warming up to 40 ℃ with 0.7 ℃/min speed, dry 6 hours, packing namely obtained described meclofenoxate hydrochloride freeze-dried powder after the assay was approved.
Preparation (the specification: 0.1g) of embodiment 4 meclofenoxate hydrochloride freeze-dried powders
Prescription:
Meclofenoxate hydrochloride compound: 100g
N.F,USP MANNITOL: 100g
Water for injection adds to 2000ml
Make 1000
Technique:
1, the meclofenoxate hydrochloride of recipe quantity is added in the water for injection of 1400ml, stirring and dissolving, inject water to 1600ml, then by recipe quantity, adds the N.F,USP MANNITOL stirring and dissolving, injects water to 2000ml, stirs.
2, add 0.10%(g/ml in 1) gac, stirred 20 minutes, filtering decarbonization, 0.22 μ m membrane filtration degerming, carry out intermediate and detect.
3, freeze-drying:
1. pre-freeze: filtrate packing false add in 2 is plugged in being cooled in advance-22 ℃ of refrigerated tanks, kept 1.5 hours, with 0.8 ℃/min speed, be cooled to-33 ℃, be incubated 2 hours;
2. distillation: open vacuum unit, control vacuum tightness is 17Pa, with 0.7 ℃/min speed, at the uniform velocity is warming up to-12 ℃, in this temperature, keeps 1 hour, with 0.5 ℃/min speed, at the uniform velocity is warming up to 3 ℃, in this temperature, keeps 5 hours.
3. dry: at the uniform velocity be warming up to 43 ℃ with 0.9 ℃/min speed, dry 6 hours, packing namely obtained described meclofenoxate hydrochloride freeze-dried powder after the assay was approved.
Preparation (the specification: 0.2g) of embodiment 5 meclofenoxate hydrochloride freeze-dried powders
Prescription:
Meclofenoxate hydrochloride compound: 100g
N.F,USP MANNITOL: 100g
Water for injection adds to 2000ml
Make 500
Technique:
1, the meclofenoxate hydrochloride compound of recipe quantity is added in the water for injection of 1400ml, stirring and dissolving, inject water to 1600ml, then by recipe quantity, adds the N.F,USP MANNITOL stirring and dissolving, injects water to 2000ml, stirs.
2, add 0.10%(g/ml in 1) gac, stirred 20 minutes, filtering decarbonization, 0.22 μ m membrane filtration degerming, carry out intermediate and detect.
3, freeze-drying:
1. pre-freeze: filtrate packing false add in 2 is plugged in being cooled in advance-22 ℃ of refrigerated tanks, kept 1.5 hours, with 0.8 ℃/min speed, be cooled to-33 ℃, be incubated 2 hours;
2. distillation: open vacuum unit, control vacuum tightness is 17Pa, with 0.7 ℃/min speed, at the uniform velocity is warming up to-12 ℃, in this temperature, keeps 1 hour, with 0.5 ℃/min speed, at the uniform velocity is warming up to 3 ℃, in this temperature, keeps 5 hours.
3. dry: at the uniform velocity be warming up to 43 ℃ with 0.9 ℃/min speed, dry 6 hours, packing namely obtained described meclofenoxate hydrochloride freeze-dried powder after the assay was approved.
Preparation (the specification: 0.25g) of embodiment 6 meclofenoxate hydrochloride freeze-dried powders
Prescription:
Meclofenoxate hydrochloride compound: 250g
N.F,USP MANNITOL: 50g
Water for injection adds to 2000ml
Make 1000
Technique:
1, the meclofenoxate hydrochloride compound of recipe quantity is added in the water for injection of 1400ml, stirring and dissolving, inject water to 1600ml, then by recipe quantity, adds the N.F,USP MANNITOL stirring and dissolving, injects water to 2000ml, stirs.
2, add 0.10%(g/ml in 1) gac, stirred 20 minutes, filtering decarbonization, 0.22 μ m membrane filtration degerming, carry out intermediate and detect.
3, freeze-drying:
1. pre-freeze: filtrate packing false add in 2 is plugged in being cooled in advance-23 ℃ of refrigerated tanks, kept 1.5 hours, with 0.7 ℃/min speed, be cooled to-35 ℃, be incubated 2 hours;
2. distillation: open vacuum unit, control vacuum tightness is 16Pa, with 0.6 ℃/min speed, at the uniform velocity is warming up to-13 ℃, in this temperature, keeps 1 hour, with 0.4 ℃/min speed, at the uniform velocity is warming up to 0 ℃, in this temperature, keeps 5 hours.
3. dry: at the uniform velocity be warming up to 41 ℃ with 0.8 ℃/min speed, dry 6 hours, packing namely obtained described meclofenoxate hydrochloride freeze-dried powder after the assay was approved.
Preparation (the specification: 0.1g) of embodiment 7 meclofenoxate hydrochloride capsules
Prescription:
Meclofenoxate hydrochloride compound: 200g
Pregelatinized Starch: 50g
Make 2000
Technique:
1, will cross successively 80 mesh sieves through meclofenoxate hydrochloride compound, the pregelatinized Starch of 60 ℃ of dryings in advance.
2, each supplementary material is fully mixed rear mensuration content, according to specification, determine loading amount, with the capsule packing machine, be packed into capsule, check, packing, obtain the medicament composition capsule that effective constituent is meclofenoxate hydrochloride of the present invention.
Preparation (the specification: 0.2g) of embodiment 8 meclofenoxate hydrochloride capsules
Prescription:
Meclofenoxate hydrochloride compound: 200g
Pregelatinized Starch: 50g
Make 1000
Technique:
1, will cross successively 80 mesh sieves through meclofenoxate hydrochloride compound, the pregelatinized Starch of 60 ℃ of dryings in advance.
2, each supplementary material is fully mixed rear mensuration content, according to specification, determine loading amount, with the capsule packing machine, be packed into capsule, check, packing, obtain the medicament composition capsule that effective constituent is meclofenoxate hydrochloride of the present invention.
Preparation (the specification: 0.1g) of embodiment 9 meclofenoxate hydrochloride dispersible tablets
Prescription:
Meclofenoxate hydrochloride compound: 200g
Microcrystalline Cellulose: 50g
Make 2000
Technique:
1, will cross successively 80 mesh sieves through meclofenoxate hydrochloride compound, the Microcrystalline Cellulose of 60 ℃ of dryings in advance.
2, each supplementary material is fully mixed rear mensuration content, according to specification, determine the sheet weight, upper machine compressing tablet, check, packing, obtain the medicament combination dispersible tablet that effective constituent is meclofenoxate hydrochloride of the present invention.
Embodiment 10 meclofenoxate hydrochloride injection sterilized powder preparation (specifications: 0.1g)
Prescription:
Meclofenoxate hydrochloride compound: 100g
Make 1000
Technique:
Under hundred grades of aseptic conditions, the meclofenoxate hydrochloride compound is undertaken aseptic subpackaged by specification, obtaining effective constituent is the meclofenoxate hydrochloride injection sterilized powder of meclofenoxate hydrochloride of the present invention.
Embodiment 11 meclofenoxate hydrochloride injection sterilized powder preparation (specifications: 0.06g)
Prescription:
Meclofenoxate hydrochloride compound: 60g
Make 1000
Technique:
Under hundred grades of aseptic conditions, the meclofenoxate hydrochloride compound is undertaken aseptic subpackaged by specification, obtaining effective constituent is the meclofenoxate hydrochloride injection sterilized powder of meclofenoxate hydrochloride of the present invention.
Embodiment 12 meclofenoxate hydrochloride injection sterilized powder preparation (specifications: 0.2g)
Prescription:
Meclofenoxate hydrochloride compound: 200g
Make 1000
Technique:
Under hundred grades of aseptic conditions, the meclofenoxate hydrochloride compound is undertaken aseptic subpackaged by specification, obtaining effective constituent is the meclofenoxate hydrochloride injection sterilized powder of meclofenoxate hydrochloride of the present invention.
Embodiment 13 meclofenoxate hydrochloride injection sterilized powder preparation (specifications: 0.25g)
Prescription:
Meclofenoxate hydrochloride compound: 250g
Make 1000
Technique:
Under hundred grades of aseptic conditions, the meclofenoxate hydrochloride compound is undertaken aseptic subpackaged by specification, obtaining effective constituent is the meclofenoxate hydrochloride injection sterilized powder of meclofenoxate hydrochloride of the present invention.
 
Below test further illustrates the present invention:
Test method is with reference to 2010 editions two appendix XIX C bulk drugs of Chinese Pharmacopoeia and pharmaceutical preparation stability test governing principle.
Sample 1: by the meclofenoxate hydrochloride compound of the embodiment of the present invention 1 method preparation.
Sample 2: commercially available meclofenoxate hydrochloride raw material.
Sample 3: by the meclofenoxate hydrochloride of China application CN103214382A embodiment 1 method preparation.
Sample 1~sample 3 is carried out the influence factor test, respectively at 60 ℃; High light (4500lx ± 500lx); 25 ℃, placed under relative humidity 90% ± 5% condition 10 days, respectively at sampling calibrating in the 10th day, result with 0 day relatively, the stability result of the investigation sample 1~table 3 that sees the following form.
60 ℃ of test-results of table 1
Figure 600336DEST_PATH_IMAGE003
Table 2 highlight test result
Table 3 high humidity test-results
Figure 600968DEST_PATH_IMAGE007
The meclofenoxate hydrochloride compound of the embodiment of the present invention 1 preparation and commercially available meclofenoxate hydrochloride raw material are carried out accelerated stability investigation (40 ℃ ± 2 ℃, RH 75% ± 5%) by commercially available back, the results are shown in Table 4.
Table 4 meclofenoxate hydrochloride compound accelerated test result
Figure 65972DEST_PATH_IMAGE009
The meclofenoxate hydrochloride compound of the embodiment of the present invention 1 preparation and commercially available meclofenoxate hydrochloride raw material are carried out permanent stability investigations (25 ℃ ± 2 ℃, RH 60% ± 10%) by commercially available back), the results are shown in Table 5.
Table 5 meclofenoxate hydrochloride compound long-term test results
Above-mentioned test-results shows, the meclofenoxate hydrochloride compound stability of the present invention's preparation is good, and foreign matter content is low, with prior art, compares and has obvious advantage.
The pharmaceutical composition with Meclofenoxate hydrochloride freeze-dried powder of the embodiment of the present invention 3 preparations and commercially available meclofenoxate hydrochloride injection freeze-dried powder are carried out accelerated stability investigation (40 ℃ ± 2 ℃, RH 75% ± 5%), the results are shown in Table 6.
Table 6 meclofenoxate hydrochloride freeze-dried powder accelerated test result
Figure 733025DEST_PATH_IMAGE013
Above-mentioned test-results shows, the effective constituent of the present invention's preparation is the lyophilized injectable powder good stability of the meclofenoxate hydrochloride for preparing of the present invention, and foreign matter content is low to be compared and have obvious advantage with prior art.
The meclofenoxate hydrochloride capsules of the embodiment of the present invention 8 preparations and commercially available meclofenoxate hydrochloride capsules are carried out accelerated stability investigation (40 ℃ ± 2 ℃, RH 75% ± 5%), the results are shown in Table 7.
Table 7 meclofenoxate hydrochloride capsules accelerated test result
Figure 334383DEST_PATH_IMAGE015
State test-results and show, the effective constituent of the present invention preparation is that the capsule stability of the meclofenoxate hydrochloride for preparing of the present invention is good, and foreign matter content is low to be compared and have obvious advantage with prior art.
The meclofenoxate hydrochloride dispersible tablet of the embodiment of the present invention 9 preparations and commercially available meclofenoxate hydrochloride dispersible tablet are carried out accelerated stability investigation (40 ℃ ± 2 ℃, RH 75% ± 5%), the results are shown in Table 8.
Table 8 meclofenoxate hydrochloride dispersible tablet accelerated test result
Figure 39296DEST_PATH_IMAGE017
Above-mentioned test-results shows, the effective constituent of the present invention's preparation is the dispersible tablet good stability of the meclofenoxate hydrochloride for preparing of the present invention, and foreign matter content is low to be compared and have obvious advantage with prior art.
The commercially available meclofenoxate hydrochloride injection sterilized powder of meclofenoxate hydrochloride injection sterilized powder of the embodiment of the present invention 10 preparations is carried out accelerated stability investigate (40 ℃ ± 2 ℃, RH 75% ± 5%), the results are shown in Table 9.
Table 9 meclofenoxate hydrochloride injection sterilized powder accelerated test result
Figure 92266DEST_PATH_IMAGE019
Above-mentioned test-results shows, the effective constituent of the present invention's preparation is the meclofenoxate hydrochloride injection sterilized powder good stability of the meclofenoxate hydrochloride for preparing of the present invention, and foreign matter content is low to be compared and have obvious advantage with prior art.

Claims (10)

1. meclofenoxate hydrochloride compound, its structural formula is as follows:
Figure 637493DEST_PATH_IMAGE001
It is characterized in that: described meclofenoxate hydrochloride compound is crystal, adopt the X-ray powder diffraction to measure, in its collection of illustrative plates, characteristic peak ° is 6.1 °, 7.7 °, 9.3 °, 12.2 °, 14.3 °, 17.8 °, 18.9 °, 20.5 °, 22.2 °, 23.3 °, 24.5 °, 25.8 °, 27.0 ° demonstrations in 2 θ ± 0.2.
2. meclofenoxate hydrochloride compound according to claim 1, it is characterized in that: the fusing point of described meclofenoxate hydrochloride compound is 147~152 ℃.
3. the preparation method of the described meclofenoxate hydrochloride compound of claim 1 or 2, comprise the steps:
It is in the mixture of the trichloromethane of 9:1 and ethanol that the meclofenoxate hydrochloride raw material is added volume ratio by weight 1:15~1:18, then 30~35 ℃ of stirring and dissolving, obtains the solution I;
Keeping solution I temperature is 30~35 ℃, add weight be the gac of meclofenoxate hydrochloride weight 0.7% in the solution I, 120~150 rev/mins were stirred 25 minutes, filtered carbon removal by 0.22 μ m membrane filtration, obtained filtrate;
Regulating the filtrate temperature is 22~27 ℃, under the stirring velocity of 90~110 rev/mins, slowly at the uniform velocity drip weight in while stirring take 50ml~75ml/min speed toward filtrate and be the ether of 8:2 and the mixing solutions of sherwood oil as the volume ratio of 10~12 times of trichloromethane in step 1) and alcohol mixtures; Simultaneously with 0.5~0.7 ℃/min speed, be cooled to 8~10 ℃, stop stirring, with 0.2~0.4 ℃/min speed, be cooled to 2~4 ℃ of standing growing the grains 6 hours, filter;
Wash 2 times with the ether of 2 times of weight filtering the filter cake obtain in step 3,47 ℃~52 ℃ dryings 8 hours, namely obtain described meclofenoxate hydrochloride compound.
4. contain the drug combination preparation of meclofenoxate hydrochloride compound, it is characterized in that: the effective constituent of described drug combination preparation is the described meclofenoxate hydrochloride compound of claim 1 or 2.
5. drug combination preparation according to claim 4, it is characterized in that: described drug combination preparation is dispersible tablet, capsule, freeze-dried powder or injectable sterile powder.
6. drug combination preparation according to claim 5, it is characterized in that: described freeze-dried powder contains pharmacy acceptable vehicle carrier, and vehicle is one or more in N.F,USP MANNITOL, glucose, dextran and lactose.
7. the preparation method of drug combination preparation claimed in claim 6, comprise the steps:
1) adding to 2000ml or meclofenoxate hydrochloride compound 250g, N.F,USP MANNITOL 50g, water for injection by meclofenoxate hydrochloride compound 60g, N.F,USP MANNITOL 240g, water for injection adds to 2000ml or meclofenoxate hydrochloride compound 100g, N.F,USP MANNITOL 100g, water for injection and adds to the recipe quantity of 2000ml, the meclofenoxate hydrochloride compound is added in the water for injection of 1400ml, stirring and dissolving, inject water to 1600ml, then add the N.F,USP MANNITOL stirring and dissolving by recipe quantity, inject water to 2000ml, stir;
2) toward 1) in add the gac of 0.10g/100ml, stirred 20 minutes, filtering decarbonization, 0.22 μ m membrane filtration degerming obtains filtrate;
3) freeze-drying:
1. pre-freeze: with 2), filtrate packing false add plugs in being cooled in advance-24 ℃~-22 ℃ refrigerated tanks, keeps 1.5 hours, with 0.6 ℃/min~0.8 ℃/min speed, is cooled to-38 ℃~-33 ℃, is incubated 2 hours;
2. distillation: open vacuum unit, control vacuum tightness is 14~17Pa, with 0.5 ℃/min~0.7 ℃/min speed, at the uniform velocity is warming up to-14 ℃~-12 ℃, in this temperature, keeps 1 hour, at the uniform velocity be warming up to-2 ℃~3 ℃ with 0.3 ℃/min~0.5 ℃/min speed, in this temperature, kept 5 hours;
3. dry: as with 0.7 ℃/min~0.9 ℃/min speed, at the uniform velocity to be warming up to 40 ℃~43 ℃, dry 6 hours, to obtain described meclofenoxate hydrochloride freeze-dried powder.
8. the preparation method of the described drug combination preparation of claim 5, is characterized in that: when described drug combination preparation is capsule
1) will cross successively 80 mesh sieves through meclofenoxate hydrochloride compound, the pregelatinized Starch of 60 ℃ of dryings in advance;
2) ratio that is 4:1 in meclofenoxate hydrochloride compound and pregelatinized Starch weight ratio is fully mixed rear mensuration content with meclofenoxate hydrochloride compound and pregelatinized Starch, determine loading amount according to specification, be packed into capsule with the capsule packing machine, check, packing, obtain the medicament composition capsule that effective constituent is the described meclofenoxate hydrochloride compound of claim 1 or 2.
9. the preparation method of the described drug combination preparation of claim 5, is characterized in that: when described drug combination preparation is dispersible tablet
1) will cross successively 80 mesh sieves through meclofenoxate hydrochloride compound, the Microcrystalline Cellulose of 60 ℃ of dryings in advance;
2) ratio that is 4:1 in meclofenoxate hydrochloride compound and Microcrystalline Cellulose weight ratio is fully mixed rear mensuration content with meclofenoxate hydrochloride compound and Microcrystalline Cellulose, each supplementary material is fully mixed rear mensuration content, determine the sheet weight according to specification, upper machine compressing tablet, check, packing, obtain the medicament combination dispersible tablet that effective constituent is the described meclofenoxate hydrochloride compound of claim 1 or 2.
10. the preparation method of the described drug combination preparation of claim 5, it is characterized in that: when described drug combination preparation was injectable sterile powder, its preparation method was:
Under hundred grades of aseptic conditions, the meclofenoxate hydrochloride compound is undertaken aseptic subpackaged by specification, obtain the injectable sterile powder that effective constituent is the described meclofenoxate hydrochloride compound of claim 1 or 2.
CN201310365846.0A 2013-08-21 2013-08-21 Meclofenoxate hydrochloride compound and pharmaceutical composition thereof Active CN103396328B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310365846.0A CN103396328B (en) 2013-08-21 2013-08-21 Meclofenoxate hydrochloride compound and pharmaceutical composition thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310365846.0A CN103396328B (en) 2013-08-21 2013-08-21 Meclofenoxate hydrochloride compound and pharmaceutical composition thereof

Publications (2)

Publication Number Publication Date
CN103396328A true CN103396328A (en) 2013-11-20
CN103396328B CN103396328B (en) 2014-10-15

Family

ID=49560110

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310365846.0A Active CN103396328B (en) 2013-08-21 2013-08-21 Meclofenoxate hydrochloride compound and pharmaceutical composition thereof

Country Status (1)

Country Link
CN (1) CN103396328B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104058979A (en) * 2014-07-02 2014-09-24 江苏汉斯通药业有限公司 Purification process of meclofenoxate hydrochloride
CN105106190A (en) * 2015-10-09 2015-12-02 杨献美 Central stimulant meclofenoxate hydrochloride composition
CN105106189A (en) * 2015-09-30 2015-12-02 杨献美 Meclofenoxate hydrochloride pharmaceutical composition capable of promoting brain energy metabolism
CN105287409A (en) * 2015-12-01 2016-02-03 青岛华之草医药科技有限公司 Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia
CN105287410A (en) * 2015-12-01 2016-02-03 青岛华之草医药科技有限公司 Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating traumatic coma
CN105434384A (en) * 2016-01-05 2016-03-30 濮阳市仲亿药业有限公司 Aceclofenac dispersible tablets and preparation method
CN113133975A (en) * 2021-04-22 2021-07-20 海南通用三洋药业有限公司 Preparation method of meclofenoxate hydrochloride freeze-dried powder injection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61171460A (en) * 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd Production of i-type crystal of meclofenoxate hydrochloride
JPS61246123A (en) * 1985-04-22 1986-11-01 Dainippon Pharmaceut Co Ltd Freeze-drying of highly concentrated aqueous solution of meclofenoxate hydrochloride
CN101747215A (en) * 2008-12-11 2010-06-23 重庆药友制药有限责任公司 Method for preparing meclofenoxate hydrochloride sterile bulk drug
CN103214382A (en) * 2013-04-24 2013-07-24 四川省惠达药业有限公司 Meclofenoxate hydrochloride compound and pharmaceutical composition thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61171460A (en) * 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd Production of i-type crystal of meclofenoxate hydrochloride
JPS61246123A (en) * 1985-04-22 1986-11-01 Dainippon Pharmaceut Co Ltd Freeze-drying of highly concentrated aqueous solution of meclofenoxate hydrochloride
CN101747215A (en) * 2008-12-11 2010-06-23 重庆药友制药有限责任公司 Method for preparing meclofenoxate hydrochloride sterile bulk drug
CN103214382A (en) * 2013-04-24 2013-07-24 四川省惠达药业有限公司 Meclofenoxate hydrochloride compound and pharmaceutical composition thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104058979A (en) * 2014-07-02 2014-09-24 江苏汉斯通药业有限公司 Purification process of meclofenoxate hydrochloride
CN105106189A (en) * 2015-09-30 2015-12-02 杨献美 Meclofenoxate hydrochloride pharmaceutical composition capable of promoting brain energy metabolism
CN105106190A (en) * 2015-10-09 2015-12-02 杨献美 Central stimulant meclofenoxate hydrochloride composition
CN105287409A (en) * 2015-12-01 2016-02-03 青岛华之草医药科技有限公司 Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia
CN105287410A (en) * 2015-12-01 2016-02-03 青岛华之草医药科技有限公司 Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating traumatic coma
CN105434384A (en) * 2016-01-05 2016-03-30 濮阳市仲亿药业有限公司 Aceclofenac dispersible tablets and preparation method
CN113133975A (en) * 2021-04-22 2021-07-20 海南通用三洋药业有限公司 Preparation method of meclofenoxate hydrochloride freeze-dried powder injection

Also Published As

Publication number Publication date
CN103396328B (en) 2014-10-15

Similar Documents

Publication Publication Date Title
CN103396328B (en) Meclofenoxate hydrochloride compound and pharmaceutical composition thereof
CN102274195B (en) Oxiracetam freeze-dried powder preparation and preparation method thereof
CN103446067A (en) Oxiracetam freeze-drying preparation for injection and preparation method thereof
CN103224539B (en) A kind of Gastrodine compound and pharmaceutical composition thereof
CN103159769B (en) Doxofylline compound and medicine composition thereof
CN103655469A (en) Prescription and preparation technology of lipoic acid injection combination
CN102321007B (en) Oxiracetam compound and preparation method as well as medicine composition thereof
CN102302461B (en) Dantrolene sodium freeze-dried powder injection for injection and preparation method thereof
CN103073542A (en) Preparation method and application of tropisetron citrate crystal form II
CN103214382B (en) Meclofenoxate hydrochloride compound and pharmaceutical composition thereof
CN102796078B (en) Pantoprazole compound, preparation methods and pharmaceutical preparations thereof
CN104013585A (en) Piracetam freeze-dried powder injection for injection and preparation method thereof
CN103494779B (en) Andrographolide powder preparation for injection and preparation method thereof
CN103040855A (en) Pharmaceutical composition of fludarabine phosphate and preparation method thereof
CN104072400B (en) Oxiracetam compound and pharmaceutical composition thereof
CN103304604B (en) Clindamycin phosphate compound and preparation method and pharmaceutical composition thereof
CN102552210B (en) Entecavir capsule and preparation method thereof
CN102670526B (en) Oxaliplatin freeze-dried powder injection and preparation method thereof
CN105503888B (en) A kind of naloxone hydrochloride crystal-form compound
CN102086178B (en) Cinepazide maleate disesquihydrate and preparation method thereof
CN105085548A (en) Pharmaceutical cefotiam composition for treating infectious diseases
CN107432860B (en) Preparation method of levo-oxiracetam freeze-dried powder
CN107281118A (en) Good levo-oxiracetam freeze-dried powder of a kind of stability and preparation method thereof
CN107303266B (en) Levo-oxiracetam injection and preparation method thereof
CN107397722B (en) (S) -4-hydroxy-2-oxo-1-pyrrolidine acetamide freeze-dried powder for injection and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: HUNAN WUZHOUTONG PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: HUBEI MERRYCLIN PHARMACEUTICALS CO., LTD.

Effective date: 20150316

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 430014 WUHAN, HUBEI PROVINCE TO: 411200 XIANGTAN, HUNAN PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20150316

Address after: 411200 Fenghuang Road, easy Town, Xiangtan County, Xiangtan, Hunan

Patentee after: HUNAN WUZHOUTONG PHARMACEUTICAL CO., LTD.

Address before: 430014, Zhenghe Plaza, 707 Zhongshan Avenue, Jiang'an District, Hubei, Wuhan, 1506

Patentee before: Hubei Merryclin Pharmaceutical Co., Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Meclofenoxate hydrochloride compound and pharmaceutical composition thereof

Effective date of registration: 20200629

Granted publication date: 20141015

Pledgee: China Construction Bank Corporation Xiangtan County sub branch

Pledgor: HUNAN WUZHOUTONG PHARMACEUTICAL Co.,Ltd.

Registration number: Y2020980003555

CP03 Change of name, title or address

Address after: No. 219, biquantan Road, Tianyi Economic Development Zone, Xiangtan City, Hunan Province

Patentee after: Hunan wuzhoutong Pharmaceutical Co., Ltd

Address before: 411200 Fenghuang Road, Yisuhe Town, Xiangtan County, Hunan Province

Patentee before: HUNAN WUZHOUTONG PHARMACEUTICAL Co.,Ltd.

CP03 Change of name, title or address